Related Experiment Video
Updated: Mar 24, 2026
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges
Raffaele De Caterina1, Shinya Goto2
1Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University - Chieti-Pescara, Pisa, Italy; G. Monasterio Foundation, Pisa, Italy.
Insights
Patients with acute coronary syndrome (ACS) benefit from triple pathway inhibition, combining antiplatelet therapy with thrombin inhibitors. This approach is crucial for preventing recurrent thrombotic events, especially in those with atrial fibrillation (AF).
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Patients post-acute coronary syndrome (ACS) face high risks of recurrent thrombotic events.
- Thrombin is central to arterial thrombus formation via platelet activation and fibrin generation.
- Current secondary prevention relies on antiplatelet therapy targeting thromboxane and P2Y12 pathways.
Purpose of the Study:
- To explore the role of additional antithrombotic treatments beyond standard antiplatelet therapy in ACS patients.
- To discuss the concept and clinical implications of "triple pathway inhibition" in ACS management.
- To highlight the necessity of combined antithrombotic strategies in ACS patients with atrial fibrillation (AF).
Main Methods:
- Review of recent clinical trial data on novel antithrombotic strategies in ACS.
- Discussion of the pathophysiology linking platelet and fibrin formation in ACS.
- Analysis of the benefits of inhibiting thrombin activity or its receptors.
Main Results:
- Clinical trials support adding thrombin inhibition to antiplatelet therapy in ACS.
- Triple pathway inhibition is an option for ACS and a necessity for ACS with AF.
- Anticoagulants are more effective than antiplatelet agents in preventing stroke in ACS with AF.
Conclusions:
- Combined inhibition of thrombin and antiplatelet therapy presents a promising strategy for ACS secondary prevention.
- Managing triple pathway inhibition requires careful consideration and patient tailoring.
- Further research is needed to optimize the clinical application of these combined antithrombotic strategies.
Abstract:
Patients after an acute coronary syndrome (ACS) are at increased risk of recurrent thrombotic events, justifying the search for additional antithrombotic treatments. The pathophysiology of ACS involves arterial thrombus formation, in turn occurring because of a combination of platelet activation and fibrin formation, with thrombin playing a key role in both. Antiplatelet therapy, targeting the thromboxane pathway and the ADP P2Y12 receptor has been widely accepted for secondary prevention after an ACS. Now, data from recent clinical trials in such patients also encourage the pursuit of inhibiting thrombin formation or thrombin-mediated platelet activation in addition to antiplatelet therapy. This "triple pathway inhibition", including inhibition of thrombin activity or thrombin receptor(s), is currently an option in pure ACS, but already a must in the setting of ACS accompanied by atrial fibrillation (AF), where anticoagulants have been shown to be much more effective than antiplatelet agents in preventing stroke. We here discuss the challenges of managing combined thrombin activity or receptor inhibition and antiplatelet therapy in all such patients. Translating this into practice still requires further studies and patient tailoring to fully exploit its potential.
More Related Videos
13:10Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
Published on: September 25, 2016
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...